Learning agility is the name of the game

Sadhna Joglekar, Sr VP and Head of Global Drug Development, Novartis shares her views on the evolving opportunities for women in R&D and clinical development, the importance of mentorship and sponsorship in leadership journeys, and why adaptability and continuous learning are key to thriving in the age of digital transformation, in an interaction with Kalyani Sharma

- 

You lead global drug development in a highly scientific and regulated environment. What do you see as the biggest opportunities for women in R&D and clinical development to step into strategic leadership roles?

That's an interesting question. If you look at the evolution of the field, you'll notice that more and more women are stepping into strategic roles even in India. For instance, in Mauritius, around 40 per cent of the workforce in R&D is women. And even at leadership levels, more than 30 per cent of leaders are women.

We have a very conscious focus on diversity and inclusion. As part of that, we ensure that our emerging and senior leaders receive the training they need to take on executive roles. It's a concerted effort to help them move to that next level. Scientifically, women are as capable as anyone else, but what often makes the difference is mentorship and sponsorship—these are crucial in helping women navigate complex leadership paths.

Women are well represented in scientific and medical functions early in their careers, but fewer transition into senior decision-making positions. What structural or cultural shifts are needed within pharma organisations to bridge this leadership gap?

I like to explain this using what I call the “three Cs”: Culture, Compensation, and Career.